Rituximab is a type I anti-CD20 monoclonal antibody, which is primarily used for treating
non-Hodgkin's B cell lymphoma [
[1]
]. Clinical efficacy, safety, and modulating effects on normal, malignant pre-B and
mature B cells have been reported [
[2]
]. It is also used off label in the treatment of several autoimmune diseases. Common
side effects are infusion-related reactions, such as fever, chills, and shivering,
which occur frequently after the first infusion and usually related to cytokines release
[
[3]
]. Other side effects are less frequent but increasingly reported. Here we present
2 cases of Rituximab related neuropathy.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A review of Rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Future Oncol. 2015; 11: 1327-1342
- Rituximab in membranous nephropathy: not all studies are created equal.Nephron. 2017; 135: 46-50
- Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study.Eur J Intern Med. 2019; 67: 59-64
- Longterm Safety of Rituximab: final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.J Rheumatol. 2015; 42: 1761-1766
- Harmonisation in Pharmacovigilance.Drug Safety. 1994; 10: 93-102
- A case of reversible posterior leucoencephalopathy syndrome after Rituximab infusion.Rheumatology (Oxford). 2004; 43: 1450-1451
- Acute demyelinating neuropathy associated with Rituximab treatment in a patient with relapsing nephrotic syndrome.CEN Case Rep. 2017; 6: 215-216
- Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following Rituximab.Muscle Nerve. 2014; 49: 457-458
- Immune regulatory function of B cells.Annu Rev Immunol. 2012; 30: 221-241
- Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with Rituximab.Haematologica. 2006; 91 (ECR17)
Article info
Publication history
Published online: March 17, 2020
Accepted:
March 10,
2020
Received in revised form:
February 17,
2020
Received:
November 10,
2019
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
